Golden autumn brings refreshing breezes and frequent good news! Building on its exceptional R&D capabilities and efficient technical services, Guangzhou DiQi Pharmaceutical Technology Co., Ltd. has achieved another milestone in September—securing a production license for the morphine sulfate sustained-release tablet project developed for Weihai Lutian Pharmaceutical Co., Ltd. This follows the successful development of compound tropicamide eye drops for Shandong Chenxin Pharmaceutical Co., Ltd. in June, which also obtained its production license.

The approved morphine sulfate extended-release tablets represent a critical sustained-release formulation for managing moderate to severe pain, characterized by high technical development complexity and stringent quality control requirements. Leveraging its extensive expertise in controlled-release technology, DiQi Pharmaceuticals Co., Ltd. successfully overcame technical challenges, ensuring efficient project advancement and achieving regulatory approval on the first submission. This demonstrates the company's robust R&D translation capabilities and quality assurance system.

The consecutive acquisition of two major approvals not only signifies our partners' high recognition of DiQi Pharmaceuticals Co., Ltd.'s technological capabilities and service quality, but also demonstrates our sustained leadership in high-end formulation R&D and technology transfer. We remain committed to a customer-centric approach, driven by technological innovation, providing partners with end-to-end solutions from R&D to industrialization.

We are grateful for your trust and will live up to your expectations! DiQi Pharmaceuticals Co., Ltd. will continue to deepen its expertise in high-end formulation technology development, collaborate with more partners, and contribute to enhancing the quality and efficiency of China's pharmaceutical industry, bringing more high-quality medicines to patients!